Cipla Q4FY22 and Year Ended result : Business grew 21% in India, PAT drops 12.4% to ₹362 Cr YoY

In India business grew 21% YoY across branded prescription, trade generics and consumer health; 15% YoY growth adjusted for covid portfolio In SAGA (SOUTH AFRICA, SUB-SAHARAN AFRICA AND GLOBAL ACCESS) region grew by 8% YoY basis in USD terms; private business grew 17%

Cipla logo
article continues after this advertisement

Cipla Ltd is a leading pharmaceutical from India with presence across the world. It was established in 1935 as Chemical Industrial & Pharmaceutical Laboratories Ltd and changed to its current name in 1984. The company has a vast portfolio with more than 1,500 products in the market. On August 17, 1935 Cipla was registered as a public limited company with an authorized capital of ₹6 lakh. The company has posted its Q4FY22 and year ended financial results today, the details are as below :

(I) Audited Consolidated Financial Results for Quarter Ended (YoY comparison):

The company has reported, a consolidated Total Income of ₹5,324.35 crore in the quarter ended on March 31, 2022 as against ₹4,666.58 crore in the corresponding quarter ended last year on Mar 31, 2021, increased by 14.10%.

The company has posted a consolidated Net Profit of ₹362.07 crore in the quarter ended on March 31, 2022 as against ₹413.38 crore in the corresponding quarter ended in last year on Mar 31, 2021. The PAT surges down by 12.41%.

The status of the EPS of the company stood at ₹4.48 as on March 31, 2022 compared to the previous quarter ended on Mar 31, 2021 which was ₹5.12, down by 12.50%.

₹*Mar 31, 2022 (Q4FY22)Dec 31, 21 (Q3FY22)Mar 31, 21 (Q4FY21)
Total Income5,324.355,570.154,666.58
Total Expenses4819.024516.044122.85
PBT /(Loss)447.831054.11543.73
Total Tax /(credit)71.11295.16128.22
PAT /(Loss) [to the owners]362.07728.60413.38
*figures are in Crores

(II) Audited Consolidated Financial Result details for the Year Ended :

The company has reported, a consolidated Total Income of ₹22,044.25 crore in the financial year ended on March 31, 2022 as against ₹19,425.58 crore for the financial year ended on Mar 31, 2021, increased by 13.58%.

The company has posted a consolidated Net Profit of ₹2,516.75 crore in the financial year ended on March 31, 2022 as against ₹2,404.87 crore for the financial year ended on March 31, 2021. The PAT surges up by 4.65%.

The status of the EPS of the company stood at ₹31.17 as on March 31, 2022 compared to the previous year ended on March 31, 2021 which was ₹29.79, up by 4.63%.

₹*Mar 31, 2022 (FY22)Mar 31, 2021 (FY21)
Total Income22,044.2519,425.58
Total Expenses18368.8616135.52
PBT /(Loss)3493.273290.06
Total Tax /(credit)933.80888.76
PAT /(Loss)2,516.752,404.87
*figures are in Crores
cipla q4 result 2022 – Market Times

(III) Key Highlights about the Performance :

  • In India business grew 21% YoY across branded prescription, trade generics and consumer health; 15% YoY growth adjusted for covid portfolio
  • In SAGA (SOUTH AFRICA, SUB-SAHARAN AFRICA AND GLOBAL ACCESS) region grew by 8% YoY basis in USD terms; private business grew 17%
  • US core formulation revenue at multi-quarter high of $160 Mn; 17% YoY growth
  • Robust momentum in core formulation business; strong traction in respiratory assets as well as contribution from peptide assets
  • EBITDA stood at ₹763 Cr; EBITDA Margin at 14.5% in Q4FY22
  • EBITDA stood at ₹4,578 C; EBITDA Margin at 21.0% in FY22
cipla q4 result 2022 – Market Times

Shares of Cipla Ltd was last traded in BSE at ₹926.25 as compared to the previous close of ₹937.55. The total number of shares traded during the day was 28013 in over 1656 trades.

The stock last hit in BSE,

  • Intraday High of ₹ 935.80
  • Intraday low of ₹ 919.00